{
  "id": 7806320,
  "title": "CVS Trading Well Below Wall Street Targets After Month’s Softening Creates Opening",
  "url": "https://urgent.news/2026/09/16/cvs-trading-well-below-wall-street-targets-after-months-softening",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-16T14:40:11.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/cvs-trading-well-below-wall-144011771.html"
  },
  "original_language": "en",
  "account": "CVS Health's shares are trading below $94, significantly lower than the average analyst price target of $116.28 and nearly half the model's one-year target of $141.05. Management has raised its adjusted EPS guidance for 2026 to a range of $7.90 to $8.10, while Q2 earnings surpassed expectations by 38%. The stock has risen 18.4% year to date and 27.8% over the trailing year, outperforming the S&P 500's 11.2% gain. However, the stock faces uncertainties related to Aetna's margin recovery, Pharmacy Benefit Manager (PBM) re-regulation, and drug pricing rules. With a forward P/E of 11x and a base-case one-year target of $141.05, the stock appears more attractive than Wall Street's current valuation. The recommendation is to buy shares, with a 49.6% upside potential, but the outcome depends on the durability of Aetna's margin recovery and the impact of PBM and drug pricing challenges.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}